Targeting PTEN: Why It Matters
Scott T. Tagawa, MD, MS
Mary-Ellen Taplin, MD
Molecular Profiling in mHSPC: Informing Treatment Selection
EHA 2026: Sonrotoclax Plus Zanubrutinib in Frontline CLL
Chan Y. Cheah, MBBS
ADT Intensification: The Evidence You Can’t Afford to Miss
Winning the Battle Against Side Effects: Adverse Event Management in HSPC
EHA 2026: Long-Term Zanubrutinib Outcomes
Alessandra Tedeschi, MD
Case: Implementing ADT Intensification in mHSPC
Addressing Oncology-Related Infertility Through Collaborative Care
Irene Su, MD, MSCE
The Evolving TROP2-directed ADC Landscape in Metastatic NSCLC
Nicolas Girard, MD
Louise Lim, MD
Jacob Sands, MD
Stephanie McDonald, MSN, FNP-BC, AOCNP
6-Year CheckMate 9LA Data in PD-L1-Negative NSCLC: Implications for Care
Steve Jackson, PharmD
Lyudmila A. Bazhenova, MD
Assessing and Interpreting pCR in Perioperative NSCLC
Alexander Spira, MD, PhD, FACP
ELEVATE: Elacestrant Plus Capivasertib in Advanced Breast Cancer
Aditya Bardia, MD, MPH, FASCO
Ongoing Trials in Oral Targeted Strategies in Breast Cancer
SERENA-6: Acting on ESR1 Mutations in Advanced Breast Cancer
Erica L. Mayer, MD, MPH
Rapid Data Pulses From ASCO 2026: Emerging Data on Oral Targeted Strategies in Breast Cancer
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Loading...
NEW FEATURES:
Tell us what you think by using the Feedback button on the right side of the page.
We're glad to see you're enjoying Global Oncology Academy… but how about a more personalized experience?
Press cancel to remain on Global Oncology Academy. Press the link below or the continue button to keep going.